Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity

被引:41
作者
Luciano, BS [1 ]
Hsu, S [1 ]
Channavajhala, PL [1 ]
Lin, LL [1 ]
Cuozzo, JW [1 ]
机构
[1] Wyeth Ayerst Res, Dept Mol Inflammat Inflammat Signaling, Cambridge, MA 02140 USA
关键词
D O I
10.1074/jbc.M403716200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cot/Tpl2/MAP3K8 is a serine/threonine kinase known to activate the ERK, p38, and JNK kinase pathways. Studies of Tpl2 knock-out mice reveal a clear defect in tumor necrosis factor-alpha production, although very little detail is known about its regulation and the signaling events involved. In the present study we demonstrated that phosphorylation of Cot was required for its maximal activity as phosphatase treatment of Cot decreased its kinase activity. The Cot sequence contains a conserved threonine at position 290 in the activation loop of the kinase domain. We found that mutation of this residue to alanine eliminated its ability to activate MEK/ ERK and NF-kappaB pathways, whereas a phosphomimetic mutation to aspartic acid could rescue the ability to activate MEK. Thr-290 was also required for robust autophosphorylation of Cot. Antibody generated to phospho-Thr-290-Cot recognized both wild-type and kinase-dead Cot, suggesting that phosphorylation of Thr-290 did not occur through autophosphorylation but via another kinase. We showed that Cot was constitutively phosphorylated at Thr-290 in transfected human embryonic kidney 293T cells as well as human monocytes as this residue was phosphorylated in unstimulated and lipopolysaccharide-stimulated cells to the same degree. Treatment with herbimycin A inhibited Cot activity in the MEK/ ERK pathway but did not inhibit phosphorylation at Thr-290. Together these results showed that phosphorylation of Cot at Thr-290 is necessary but not sufficient for full kinase activity in the MEK/ ERK pathway.
引用
收藏
页码:52117 / 52123
页数:7
相关论文
共 41 条
[1]   Cot kinase activates tumor necrosis factor-α gene expression in a cyclosporin A-resistant manner [J].
Ballester, A ;
Velasco, A ;
Tobeña, R ;
Alemany, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14099-14106
[2]   NF-κB1 p105 negatively regulates TPL-2 MEK kinase activity [J].
Beinke, S ;
Deka, J ;
Lang, V ;
Belich, MP ;
Walker, PA ;
Howell, S ;
Smerdon, SJ ;
Gamblin, SJ ;
Ley, SC .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (14) :4739-4752
[3]   TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105 [J].
Belich, MP ;
Salmerón, A ;
Johnston, LH ;
Ley, SC .
NATURE, 1999, 397 (6717) :363-368
[4]  
Bondeson J, 2001, INT J CLIN PRACT, V55, P211
[5]   15-deoxy-Δ12,14-prostaglandin J2 regulates endogenous cot MAPK kinase kinase 1 activity induced by lipopolysaccharide [J].
Caivano, M ;
Rodriguez, C ;
Cohen, P ;
Alemany, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) :52124-52130
[6]   Regulation of novel protein kinase C ε by phosphorylation [J].
Cenni, V ;
Döppler, H ;
Sonnenburg, ED ;
Maraldi, N ;
Newton, AC ;
Toker, A .
BIOCHEMICAL JOURNAL, 2002, 363 (03) :537-545
[7]   Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2 [J].
Chadee, DN ;
Yuasa, T ;
Kyriakis, JM .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (03) :737-749
[8]   Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling [J].
Channavajhala, PL ;
Wu, LY ;
Cuozzo, JW ;
Hall, JP ;
Liu, W ;
Lin, LL ;
Zhang, YH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (47) :47089-47097
[9]   Multiple mitogen-activated protein kinase signaling pathways connect the Cot oncoprotein to the c-jun promoter and to cellular transformation [J].
Chiariello, M ;
Marinissen, MJ ;
Gutkind, JS .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (05) :1747-1758
[10]   Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barre syndrome [J].
Creange, A ;
Belec, L ;
Clair, B ;
Raphael, JC ;
Gherardi, RK .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 68 (1-2) :95-99